Pharmabiz2h
Clearside Biomedical presents additional data from CLS-AX ODYSSEY phase 2b trial at Angiogenesis, Exudation & Degeneration 2025 meeting
Alpharetta, Georgia Wednesday, February 12, 2025, 16:30 Hrs [IST] ...
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...
ophthalmologytimes1d
Clearside Biomedical presents new data from CLS-AX ODYSSEY phase 2b trial
The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...
Morningstar2d
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
were presented at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The data were presented by Michael Singer, M.D., Clinical Professor of Ophthalmology at ...
4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry point
D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...
ophthalmologytimes1d
4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
Science Daily23h
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Too Old to Operate2d
Development of machine learning prognostic models for overall survival of epithelial ovarian cancer patients: a seer-based study.
To develop a machine learning (ML) algorithm to predict survival probabilities for patients with epithelial ovarian cancer (EOC).Data were obtained from the SEER database for women diagnosed with EOC ...
Too Old to Operate2d
Frail Patients’ ICU Admission and Mortality Across Regions
The following is a summary of “Regional differences in triage decisions affect hospital mortality among frail COVID-19 patients in the COvid MEdicaTion study,” published in the February 2025 issue of ...
Armed robbery in Revesby2d
Target Genes Found in Canine Liver Cancer Therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...
manilatimes1d
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...